Cargando…
Flourish of Proton and Carbon Ion Radiotherapy in China
Proton and heavy ion therapy offer superior relative biological effectiveness (RBE) in the treatment of deep-seated tumors compared with conventional photon radiotherapy due to its Bragg-peak feature of energy deposition in organs. Many proton and carbon ion therapy centers are active all over the w...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882681/ https://www.ncbi.nlm.nih.gov/pubmed/35237518 http://dx.doi.org/10.3389/fonc.2022.819905 |
_version_ | 1784659750606077952 |
---|---|
author | Li, Yue Li, Xiaoman Yang, Jiancheng Wang, Sicheng Tang, Meitang Xia, Jiawen Gao, Yunzhe |
author_facet | Li, Yue Li, Xiaoman Yang, Jiancheng Wang, Sicheng Tang, Meitang Xia, Jiawen Gao, Yunzhe |
author_sort | Li, Yue |
collection | PubMed |
description | Proton and heavy ion therapy offer superior relative biological effectiveness (RBE) in the treatment of deep-seated tumors compared with conventional photon radiotherapy due to its Bragg-peak feature of energy deposition in organs. Many proton and carbon ion therapy centers are active all over the world. At present, five particle radiotherapy institutes have been built and are receiving patient in China, mainly including Wanjie Proton Therapy Center (WPTC), Shanghai Proton Heavy Ion Center (SPHIC), Heavy Ion Cancer Treatment Center (HIMM), Chang Gung Memorial Hospital (CGMH), and Ruijin Hospital affiliated with Jiao Tong University. Many cancer patients have benefited from ion therapy, showing unique advantages over surgery and chemotherapy. By the end of 2020, nearly 8,000 patients had been treated with proton, carbon ion or carbon ion combined with proton therapy. So far, there is no systemic review for proton and carbon ion therapy facility and clinical outcome in China. We reviewed the development of proton and heavy ion therapy, as well as providing the representative clinical data and future directions for particle therapy in China. It has important guiding significance for the design and construction of new particle therapy center and patients’ choice of treatment equipment. |
format | Online Article Text |
id | pubmed-8882681 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88826812022-03-01 Flourish of Proton and Carbon Ion Radiotherapy in China Li, Yue Li, Xiaoman Yang, Jiancheng Wang, Sicheng Tang, Meitang Xia, Jiawen Gao, Yunzhe Front Oncol Oncology Proton and heavy ion therapy offer superior relative biological effectiveness (RBE) in the treatment of deep-seated tumors compared with conventional photon radiotherapy due to its Bragg-peak feature of energy deposition in organs. Many proton and carbon ion therapy centers are active all over the world. At present, five particle radiotherapy institutes have been built and are receiving patient in China, mainly including Wanjie Proton Therapy Center (WPTC), Shanghai Proton Heavy Ion Center (SPHIC), Heavy Ion Cancer Treatment Center (HIMM), Chang Gung Memorial Hospital (CGMH), and Ruijin Hospital affiliated with Jiao Tong University. Many cancer patients have benefited from ion therapy, showing unique advantages over surgery and chemotherapy. By the end of 2020, nearly 8,000 patients had been treated with proton, carbon ion or carbon ion combined with proton therapy. So far, there is no systemic review for proton and carbon ion therapy facility and clinical outcome in China. We reviewed the development of proton and heavy ion therapy, as well as providing the representative clinical data and future directions for particle therapy in China. It has important guiding significance for the design and construction of new particle therapy center and patients’ choice of treatment equipment. Frontiers Media S.A. 2022-02-14 /pmc/articles/PMC8882681/ /pubmed/35237518 http://dx.doi.org/10.3389/fonc.2022.819905 Text en Copyright © 2022 Li, Li, Yang, Wang, Tang, Xia and Gao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Li, Yue Li, Xiaoman Yang, Jiancheng Wang, Sicheng Tang, Meitang Xia, Jiawen Gao, Yunzhe Flourish of Proton and Carbon Ion Radiotherapy in China |
title | Flourish of Proton and Carbon Ion Radiotherapy in China |
title_full | Flourish of Proton and Carbon Ion Radiotherapy in China |
title_fullStr | Flourish of Proton and Carbon Ion Radiotherapy in China |
title_full_unstemmed | Flourish of Proton and Carbon Ion Radiotherapy in China |
title_short | Flourish of Proton and Carbon Ion Radiotherapy in China |
title_sort | flourish of proton and carbon ion radiotherapy in china |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882681/ https://www.ncbi.nlm.nih.gov/pubmed/35237518 http://dx.doi.org/10.3389/fonc.2022.819905 |
work_keys_str_mv | AT liyue flourishofprotonandcarbonionradiotherapyinchina AT lixiaoman flourishofprotonandcarbonionradiotherapyinchina AT yangjiancheng flourishofprotonandcarbonionradiotherapyinchina AT wangsicheng flourishofprotonandcarbonionradiotherapyinchina AT tangmeitang flourishofprotonandcarbonionradiotherapyinchina AT xiajiawen flourishofprotonandcarbonionradiotherapyinchina AT gaoyunzhe flourishofprotonandcarbonionradiotherapyinchina |